



Leveraging BASF's Skin Delivery Portfolio to Resolve Topical and Transdermal Challenges

BASF offers an unparalleled portfolio of excipients for topical and transdermal formulations, enabling customers to create the ideal skin delivery formulation. Based on 150 years of industry experience in oleochemistry, our premium solutions are designed to meet versatile topical and transdermal challenges. Leverage BASF's technical expertise in excipient functionality to enhance dermal drug delivery, improve formulation mildness, achieve target sensory profiles, and optimize formulation design.


We create chemistry

Pharma Solutions. Focusing on your needs with platform solutions.

Follow us on Twitter: [BASF_Pharma](#) | [www.pharma.basf.com](#)



BASF's skin delivery portfolio of excipients

BASF is the global market leader in dermatological ingredients. Committed to maintaining the highest level of quality, BASF has a wide range of functional excipients including solubilizers and penetration enhancers, emulsifiers, structuring agents, gelling agents, film formers, plasticizers, and matrix builders to support effective API delivery. To enhance patient compliance and acceptance, BASF's vast portfolio of excipients has been strategically curated to address the needs of topical and transdermal formulators.

BASF product lines

Kollicream® | **Kollisolv®** | **Kolliphor®** | **Kolliwax®** | **Kollicoat®** | **Kollidon®** | **Novata®** | **Soluplus®**

	Kollicream®	Kollisolv®	Kolliphor®	Kolliwax®	Kollicoat®	Kollidon®	Novata®	Soluplus®
Emollients & Solvents	■	■						
Penetration Enhancers	■	■						
Emulsifiers		■	■	■				
Structuring Agents		■	■	■				
Gelling Agents			■					
Matrix Builders				■	■	■	■	
Transdermal Solubilizers	■	■	■			■		■
Film Formers					■	■		■
Plasticizers		■	■					

BASF's pharmaceutical-grade dermatological excipients satisfy all the relevant regulatory requirements. Our integrated quality management is certified in line with the highest quality standards – providing you with products you can trust.

BASF offers a diverse array of informational handouts and easy-to-use formularies. Reach out to us at pharma-solutions@basf.com to request your copy and learn how to optimize excipient functionality to enhance formulation design.



Handouts

- Exploring topical semisolid microstructure
- Kollicream® 3C, IPM, OD, and OA for the development of topical and transdermal formulations
- The role of excipient selection in formulating topical therapies for sensitive skin, atopic dermatitis, and psoriasis
- Development of robust topical formulations with Kolliwax® fatty alcohols
- Poloxamers as gelling agents for topical formulations
- Investigating the tunability of poloxamer 338 and 407 gels
- Exploring the development of an anhydrous substitute for petrolatum
- Formulating topical film formers with Kollicoat® SR 30 D and Kollidon® 90 F
- Novata® B-based formulations for suppositories

Formularies

- Semisolids formulary
- PVP-Iodine formulary
- Film formers formulary

BASF has designed a series of short knowledge sharing sessions covering various topics. Kindly let us know your topics of interest from the below offerings and we will gladly set up an online session with your team.

BASF skin delivery pillars

1. BASF skin delivery platform introduction
2. Enhancing sensory profiles of topical formulations with BASF excipients and expertise
3. Enhancing the formulation of topical therapies with clinically tested mild excipients
4. Improving topical and transdermal drug delivery with BASF excipients
5. Enhancing product attributes with topical semi-solid microstructure

Application of technical expertise in formulation development


1. Using BASF skin delivery excipients to formulate topical dosage forms
2. Developing topical film formers with BASF skin delivery excipients
3. Using quality by design to optimize the product development process

Topical and transdermal formulation development guided by excipient selection

1. Optimizing topical and transdermal drug penetration with Kollicream® emollients
2. Enhancing topical formulation stability and drug permeation with Kolliwax® fatty alcohols
3. Modifying API permeation through human skin with lipid-based oleochemical excipients

Exploration of excipient functionality

1. Kollicream® OD (octyldodecanol)
2. Kollicream® 3C (cocoyl caprylocaprate)
3. Kolliwax® GMS II (glycerol monostearate 40-55 [type II])



Our service offer

If you need further support or information please contact:

North America

Norman Richardson
norman.richardson@basf.com

South America

Joao Marcos Cabral de Assis
joao-marcos.assis@basf.com

Asia Pacific

Ritu Arno
ritu.arno@basf.com

Europe

Francois Xavier Simon
francois-xavier.simon@basf.com



This document, or any information provided herein does not constitute a legally binding obligation of BASF and has been prepared in good faith and is believed to be accurate as of the date of issuance. Unless expressly agreed otherwise in writing in a supply contract or other written agreement between you and BASF:

- (a) To the fullest extent not prohibited by the applicable laws, BASF EXPRESSLY DISCLAIMS ALL OTHER REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, BY FACT OR LAW, INCLUDING ANY IMPLIED WARRANTIES, REPRESENTATIONS OR CONDITIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, SATISFACTORY QUALITY, NON-INFRINGEMENT, AND ANY REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES, ARISING FROM STATUTE, COURSE OF DEALING OR USAGE OF TRADE and BASF HEREBY EXPRESSLY EXCLUDES AND DISCLAIMS ANY LIABILITY RESULTING FROM OR IN CONNECTION WITH THIS DOCUMENT OR ANY INFORMATION PROVIDED HEREIN, including, without limitation, any liability for any direct, consequential, special, or punitive damages relating to or arising there from, except in cases of (i) death or personal injury to the extent caused by BASF's sole negligence, (ii) BASF's willful misconduct, fraud or fraudulent misrepresentation or (iii) any matter in respect of which it would be unlawful for BASF to exclude or restrict liability under the applicable laws;
- (b) Any information provided herein can be changed at BASF's sole discretion anytime and neither this document nor the information provided herein may be relied upon to satisfy from any and all obligations you may have to undertake your own inspections and evaluations;
- (c) BASF rejects any obligation to, and will not, automatically update this document and any information provided herein, unless required by applicable law; and
- (d) The user is responsible for confirming that the user has retrieved the most current version of this document from BASF as appropriate

March, 2020

For more information visit us on

www.pharma.basf.com



Get your sample today!
pharma-solutions@basf.com